CTLA4 and non-small cell lung carcinoma: Similarly, another retrospective study investigated the safety and efficacy of immunotherapy rechallenge in NSCLC patients after the onset of irAEs: in this analysis, 24 out of 38 patients (63%) patients received anti-PD-1 or anti-PD-L1 as monotherapy, while 14 (37%) patients received a combination with an anti-CTLA-4 as initial immunotherapy [51].